entertainment -WSS

entertainment

author：hotspot 2025-10-02 22:00:41 - browse：553

health care AI border between health care and tech — Adobe

There’s been significant investment in companies creating artificial intelligence (AI) applications for health and health care over the last decade. But while there have been successes, notably in the area of medical imaging, the industry is known more for not yet living up to its potential — think IBM Watson.

The slow pace of AI adoption in health care stems from the fact that health AI sits on the border between two large industries, health care and tech. And like the border between two nations, there are significant differences on either side.

During my career, I have spent time on each side. Now, as the CEO of a company on the border, I’ve developed a deeper understanding of the differences that create barriers to mutual innovation. For health AI to achieve its potential, health care and tech companies must keep the big picture top of mind: health care is about saving lives.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Mirador, a new biotech startup, launches with $400 million

WSS

Medical devices makers are asking for forgiveness, not permission

Surgeons perform first xenotransplant using CRISPR'd pig kidney

Grail spinoff by Illumina should end disastrous merger attempt

SNAP should offer more nutrition education

Surgeons perform first xenotransplant using CRISPR'd pig kidney

Hospitals owned by private equity see complications spike 25%

focus

entertainment

hotspot

Moonlake's readout produced a cash windfall. Risks remain

Diabetes management: Digital health tools fall short, study says

DIEP, the 'gold standard' of breast reconstruction, is under threat

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

Novavax promises a turnaround & Lilly roils the obesity market

SNAP should offer more nutrition education

DIEP, the 'gold standard' of breast reconstruction, is under threat

'Patient friction coefficient' can gauge a clinical trial's patient burden

Affirmative action in medical school literally saved lives

Albert Bourla of Pfizer: worst biopharma CEO of 2023

hotspot

Pfizer, Moderna say biotech, pharma drug development is a sprint

Albert Bourla of Pfizer: worst biopharma CEO of 2023

CRISPR technology availability, affordability needs to be expanded

Readout Newsletter: Illumina, CRISPR, Regeneron

Cancer, immunology, HIV research ensnared in fetal tissue politics

Mirador, a new biotech startup, launches with $400 million

explore

knowledge

entertainment

hotspot